A5089380920- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Urban and Freight Transport Logistics
- Immunodeficiency and Autoimmune Disorders
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Maritime Ports and Logistics
- Acute Myeloid Leukemia Research
- Sharing Economy and Platforms
- Lung Cancer Treatments and Mutations
- SARS-CoV-2 and COVID-19 Research
- Hematopoietic Stem Cell Transplantation
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- COVID-19 Clinical Research Studies
- Mast cells and histamine
- Long-Term Effects of COVID-19
- Renal Transplantation Outcomes and Treatments
- Transportation and Mobility Innovations
- Cancer therapeutics and mechanisms
- Pneumocystis jirovecii pneumonia detection and treatment
- Smart Parking Systems Research
- Transportation Planning and Optimization
- Multiple and Secondary Primary Cancers
Hospital San Pedro
2004-2025
King's College London
2014-2016
Laboratoire Aménagement Économie Transports
2010-2015
King's College Hospital
2014
Complejo Hospitalario de Navarra
2012
Hospital Universitario Infanta Sofía
2009
Hospital Obispo Polanco
2004
Hospital San Pedro de Alcántara
2004
<title>Abstract</title> NK-cell antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the main mechanisms action anti-CD20 monoclonal antibodies, which may affect outcome patients with chronic lymphocytic leukemia (CLL). We assessed whether high post-treatment count in peripheral blood was associated increased negative minimal residual disease (MRD) receiving antibody-based therapy. Obinutuzumab forces interaction between NK cells and CLL cells, making number critical for efficacy...
Obinutuzumab induces NK cell antibody-dependent cell-mediated cytotoxicity.Investigate the effects on human immune system after obinutuzumab monotherapy treatment in patients with chronic lymphocytic leukemia (CLL).To evaluate these effects, we analyzed distribution of CD4+ and CD8+ T cells, B cells peripheral blood eight CLL who were treated monotherapy. The lymphocytes was examined prior to each dose 24-72 h first 1000 mg complete (cycle 1 day 2). We also repeated measurements 3 months...
Anti-cluster of differentiation 20 (CD20) monoclonal antibodies (mAbs) have shown promise in follicular lymphoma (FL) as post-induction therapy, by enhancing antibody-dependent cellular cytotoxicity (ADCC). However, cytotoxic cells are reduced after this treatment. We hypothesised that ex vivo expanded lymphokine-activated killer (LAK) administered to FL-remission patients safe and improve anti-CD20 efficacy. This open, prospective, phase II, single-arm study assessed safety efficacy LAK...
3567 Background: X has superior efficacy and improved safety compared to bolus 5-FU/LV in 1st line MCRC preserves its advantage pts >65 the adjuvant setting. We investigated use an elderly pt population. Methods: Objectives were determine of twice daily oral as therapy with histologically confirmed MCRC. Pts not candidates for combination therapy, aged >70 years no prior chemotherapy (except adjuvant), measurable disease (RECIST), ECOG PS ≤2 adequate bone marrow, renal hepatic function. They...
4053 Background: K-Ras mutations in CRC primaries may predict resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, but we don´t know its behaviour metastatic tissue. The aims of this study were: 1) Evaluate the grade concordance status between primary and related samples 2) Establish a correlation k-ras individual clinicopathological features Methods: K-ras were retrospectively analysed tumours 124 patients 138 sites. tumour site was colon 87 rectum 37. Sites...
Reduced-intensity conditioning with lymphocyte-depletion to prevent graft versus host disease enables successful HSCT for patients AML/MDS, but risk of relapse is high. We have previously reported that given pre-emptive donor lymphocyte infusions (DLI) after reverse falling T-cell chimerism significantly improved relapse-free survival (Biol. Blood Marrow Transplant 19:562 2013). To investigate the basis better outcome, composition fludarabine and busulphan was assessed. Most notable,...
Invasive fungal infections are a major cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). This provides clear rationale for antifungal prophylaxis in this population. A concern is the potential drug interactions, given that most antifungals metabolized through P450 cytochrome system.We present case 33-year-old woman, with past history high-risk epilepsy, who underwent allogeneic HSCT myelodysplastic syndrome. Anidulafungin was successfully used as to...
To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab ibrutinib on natural (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients.The distribution peripheral blood NK cells 31 patients was analyzed by flow cytometry.We detected a decrease below normal range after treatment. During maintenance treatment with rituximab, an reduction less pronounced than treatment, despite infusions.After one dose...
Obinutuzumab is an engineered monoclonal antibody designed to attack and destroy targeted B-cells, both directly together with the human immune system. Natural Killer (NK) cells represent innate system that fights against tumors induces NK cell antibody-dependent cell-mediated cytotoxicity (ADCC). In our study, we confirm monotherapy produces depletion in peripheral blood of patients Chronic Lymphocytic Leukemia (CLL). This may be reversible achieve complete elimination neoplastic CLL...
Introduction: Anti-CD20 monoclonal antibodies (mAbs) have shown promise infollicular lymphoma (FL) as post-induction therapy by enhancing antibody-dependent cellular cytotoxicity (ADCC). However, cytotoxic effector cells are reduced in FL patients receiving this treatment. We hypothesized that administration of ex vivoexpanded lymphokine-activated killer (LAK) to remission is safe and improves the efficacy concomitantly administered anti-CD20 mAbs. Methods: This a multicenter open,...